COVID-19 vaccine developer wins licensing deal for temperature-stable oral capsule tech

14 January 2021
coronavirus_credit_deposit_photos-_largre

UK-based biotechnology iosBio, which is developing next-generation vaccines that can be administered orally, has entered an exclusive worldwide licensing agreement with US immunotherapy firm ImmunityBio, for iosBio’s OraPro vaccine platform technology currently being investigated in trials of ImmunityBio’s second-generation human Adeno (hAd5) COVID-19 vaccine candidate.

OraPro is iosBio’s patented oral delivery vaccine platform technology that enables oral administration of thermally-stable, viral vector vaccines. These vaccine vectors are engineered to withstand temperatures of up to 50°C, allowing them to pass through the hostile conditions in the stomach without loss of efficacy and providing long-term product stability at ambient temperatures. Oral administration delivers the vaccine directly to mucosal associated lymphoid tissue (MALT), generating mucosal, systemic and T-cell immune responses.

Under the terms of the licensing agreement, iosBio has granted ImmunityBio exclusive rights to utilize its OraPro platform technology for the oral delivery of ImmunityBio’s human Adeno (hAd5) COVID-19 vaccine candidate. iosBio will be eligible to receive royalties on net worldwide sales of the approved oral vaccine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology